Neuromeka KRX:348340KOSDAQ
뉴로메카 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days3
DART filings, 7 days1
Articles tracked3since Sep 11
In Q2 2026, Neuromeka reported revenue of ₩2.8bn, down 17.9% year on year, and an operating loss of ₩5.3bn. Neuromeka (뉴로메카) appeared in 3 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Sep 11 with 2 articles.
Neuromeka quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.8bn | -17.9% | −₩5.3bn | −₩4.6bn |
| Q1 2026 | ₩3.0bn | -5.7% | −₩4.3bn | −₩25.7bn |
| Q4 2025 derived | ₩7.9bn | -2.3% | −₩3.5bn | −₩5.7bn |
| Q3 2025 | ₩4.5bn | -28.2% | −₩3.2bn | −₩4.3bn |
| Q2 2025 | ₩3.4bn | -53.2% | −₩4.2bn | −₩4.6bn |
| Q1 2025 | ₩3.2bn | -12.8% | −₩4.0bn | −₩7.3bn |
| Q4 2024 derived | ₩8.1bn | +21.8% | −₩3.8bn | −₩4.0bn |
| Q3 2024 | ₩6.2bn | +101.7% | −₩5.7bn | −₩6.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Neuromeka top stories 2 weeks, by number of outlets
- 1
- 2
- 3
